A B S T R A C T The central nervous system (CNS) mechanism(s) for the release of antidiuretic hormone (ADH) by various stimuli is unknown. In this study, the role of CNS catecholamines in effecting ADH release was examined in conscious rats 10-14 d after the cerebroventricular injection of 6-hydroxydopamine (6-OHDA). This dose of 6-OHDA caused a 67% depletion of brain tissue norepinephrine and only 3% depletion of heart norepinephrine, as compared with controls, which were injected with the vehicle buffer alone. Either intravenous 3% saline (osmotic stimulus) or intraperitoneal hyperoncotic dextran (nonosmotic stimulus) was administered to water-diuresing rats through indwelling catheters. Neither of these maneuvers changed arterial pressure, pulse, or inulin clearance in control or 6-OHDA rats. The 3% saline caused similar increases in plasma osmolality (15 mosmol/kg H2O) in control and 6-OHDA rats. The control rats, however, increased urinary osmolality (Uosm) to 586 mosmol/kg H20, whereas 6-OHDA rats increased Uosm only to 335 mosmol/kg H20 (P < 0.005). These changes in Uosm were accompanied by an increase in plasma ADH to 7.6 ,uIU/ml in control animals vs. 2.9 ,IU/ml in 6-OHDA rats (P < 0.005). All waterdiuresing animals had undetectable plasma ADH levels. Dextran-induced hypovolemia caused similar decrements (-10%) in blood volume in both control and 6-OHDA animals, neither of which had significant changes in plasma osmolality. This nonosmotic hypovolemic stimulus caused an increase in Uosm to 753
A B S T R A C T The central nervous system (CNS) mechanism(s) for the release of antidiuretic hormone (ADH) by various stimuli is unknown. In this study, the role of CNS catecholamines in effecting ADH release was examined in conscious rats 10-14 d after the cerebroventricular injection of 6-hydroxydopamine . This dose of 6-OHDA caused a 67% depletion of brain tissue norepinephrine and only 3% depletion of heart norepinephrine, as compared with controls, which were injected with the vehicle buffer alone. Either intravenous 3% saline (osmotic stimulus) or intraperitoneal hyperoncotic dextran (nonosmotic stimulus) was administered to water-diuresing rats through indwelling catheters. Neither of these maneuvers changed arterial pressure, pulse, or inulin clearance in control or 6-OHDA rats. The 3% saline caused similar increases in plasma osmolality (15 mosmol/kg H2O) in control and 6-OHDA rats. The control rats, however, increased urinary osmolality (Uosm) to 586 mosmol/kg H20, whereas 6-OHDA rats increased Uosm only to 335 mosmol/kg H20 (P < 0.005). These changes in Uosm were accompanied by an increase in plasma ADH to 7.6 ,uIU/ml in control animals vs. 2.9 ,IU/ml in 6-OHDA rats (P < 0.005). All waterdiuresing animals had undetectable plasma ADH levels. Dextran-induced hypovolemia caused similar decrements (-10%) in blood volume in both control and 6-OHDA animals, neither of which had significant changes in plasma osmolality. This nonosmotic hypovolemic stimulus caused an increase in Uosm to 753 INTRODUCTION During the 40 yr since the original studies of Rydin and Verney (1) there has been considerable interest in the role of the sympathetic nervous system in renal water excretion. In these early studies of Verney (2) the antidiuresis associated with electrical stimulation of dog's flanks ("emotional stress") was enhanced by sympathetic denervation procedures and impaired by either intravenous epinephrine or tyramine administration. Because neither of these latter sympathomimetic agents altered the antidiuretic response to the administration ofposterior pituitary extract, Verney suggested (2) that sympathetic stimulation may inhibit a sequence of chemical events in the central nervous system which leads to the release of antidiuretic hormone (ADH). 1 The possibility, however, that catecholamines may interfere with the effect ofADH at the level ofthe renal tubule was proposed later on the basis ofin vitro studies in anuran me'mbranes (3), canine renal medullary tissue (4) , and intact man (5) . Recent studies in ADH deficiency in dog (6, 7) , rat (8) , and man (9) , however, have demonstrated that the primary in vivo effect of catecholamines on water excretion is modulated by altering eindogenous ADH release. These latter resuilts this sul)port the original hypothesis of Verney that stuggested a primlary central effect of catecholamiiines on ADH release. Hlowever, in contrast to the proposal of a direct cenitral effect of catecholamines on ADH release, the effects of both alpha (10) and beta adrenergic stimulation (11) on ADH release, are me(liated bv extracerebral arterial baroreceptors, pathways that now appear to nmodulate many nonosmiotic stimuli for ADH release (12) .
The possibility remains, however, that intracerebral catecholaminies mnay be important as central neturotransmitters in eitlher the osmllotic or nioInosImlotic release of ADII, or both (13, 14) . Some in vivo evidence for such a role of catecholamiiines has been obtained by the demonstrationi that the intracerebral injection of norepinephrine stimtulates ADH release, an effect which can be blocked by alpha adrenergic blockade (15) (16) (17) . Althouigh this antidiuretic effect of central norepinephrinie adminiistrationi (15) is opposite from the water diuresis induced by intravenous norepiniephrine (10) , it must be remembered that the cenitral and peripheral effects of alpha adrenergic stimutlation on blood pressuire also are in the opposite direction (18) . In this regard it is important to note that systemic drug administration may bring into play a variety of efferent reflex mechanismns as a resuilt of the effects of the drug on systemuic hemodynamics. Likewise, somiie cauition should be exercised in interpreting the restults of stuidies with the acute intracerebral injection of stupraphysiological doses of various drugs. In this regard, it seems rather clear that the in vivo interruption of parasympathetic afferent pathways to the brain stimulates ADH release (19) , whereas activation of the efferent limb of the autonomic nervous system by intracerebral injections of acetylcholine and carbachol also has been founld to stimtulate ADH release (15, 17) .
In this study another approach has been used in conscious rats to evaluate the potential importainee of' brain catecholamiiines on ADH release. Brain catecholamines were depleted chemically by the uise of' intraventricular 6-hydroxydopamine (6-OH DA), a procedure which does not alter catecholamine stores in extracerebral tissues. (25) . In our laboratory the osmolality of five samples of rat and dog plasma were determined in quintuplicate by this method. The greatest variation of any single measurement from the mean was 1.3% (4 mosmol).
Next, an infusion of 0.33% saline with 1,200 mg inulin/100 ml was started at a rate of9 ml/h (model 355, Sage Instruments Div., Orion Research Inc., Cambridge, Mass.). In most cases, a volume equaling -3% of body weight was administered as Uosm fell to below 150 mosmollkg. Once a stable water diuresis was achieved, three 5-min urine collections were made for Uosm, volume, and inulin concentration (AutoAnalyzer, Technicon Instruments Corp., Tarrytown, N. Y.). Simultaneous 0.2-ml blood samples were taken for Hct, plasma osmolality (Posm), and inulin. Blood pressure and pulse were continuously monitored by a strain gauge (model 267AC, model 7702B, Hewlett-Packard Co., Palo Alto Calif.) connected to the arterial line.
After the control period an infusion of 3% saline, 2 ml/100 g body wt, was administered over a period of 4-6 min. Blood pressure, pulse, and respirations were monitored continuously throughout this infusion. After completing the infusion, the experimental periods were started and urine was collected at 5-min intervals and blood samples, 0.2 ml, were taken every 10 min until a postcontrol water diuresis occurred (Uosm < 150 mosmol/kg). At this time the hypotonic infusion was discontinued and the animals were sacrificed. Tissue was removed for assay of catecholamine concentrations as described below.
Another group of 6-OHDA-injected and control-injected animals received the hypertonic saline infusion and had blood ADH levels measured. Because the maximum urinary concentration after hypertonic saline was found in earlier experiments to occur between 18 and 23 min, all animals in this group had 2 ml of blood for ADH removed rapidly over 10 s through the arterial catheter exactly 20 min after the start of the experimental period. As a control to establish that blood removal over 10 s did not stimulate ADH release rapidly enough to effect the ADH level in the withdrawn blood specimen, a group of control-injected and 6-OHDA-injected animals had ADH levels drawn over a 10-s period while undergoing a water diuresis.
Hyperoncotic dextran protocol. As a nonosmotic, hypovolemic stimulus to ADH release, the intraperitoneal administration of 6% dextran-70 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) was used. Rats were prepared in the same manner as described above for the hypertonic saline protocol, with the exception of placement of an indwelling peritoneal catheter (PE 250, Clay-Adams) at the time of surgery. After establishing a water diuresis as described above, collection of appropriate control blood and urine samples were obtained. The animals then received intraperitoneal dextran (1.8 ml/100 g body wt) at a rate of 1 ml/min. The estimated oncotic pressure of this solution (van't Hoff equation) was 800 mm H20. Blood pressure, pulse, and respiration were monitored throughout the infusion. Urine was then collected at 5-min intervals and 0.2 ml of blood was taken every 10 min for a period of 60 min after dextran administration (experimental period). Blood removed was replaced with equivalent volumes of isotonic saline. The hypotonic infusion was then stopped and the animals sacrificed. Tissue was then obtained and prepared for the catecholamine assay. Calculation of estimated changes in blood volume (BV) was done by the formula [ABV = 1 -(Hct 2/Hct 1)]. This method probably underestimates ABV because it does not account for erythrocyte volume removed by blood sampling.
As in the hypertonic saline protocol a separate set ofanimals was then studied for ADH levels. Because the time of peak Uosm after dextran varied from 30 to 60 min, a summed sampling technique was used for blood ADH samples. With this technique, 0.1 ml of blood was drawn at 30 min, and then similar samples were drawn every 3 min for the next 30 min. Blood ADH was then measured on the pooled specimens. Blood pressure and pulse were monitored throughout the experiments. Samples of blood (Hct, Posm, inulin) and urine (volume, Uosm, inulin) were also taken. Animals were then sacrificed, and tissue was obtained and prepared for catecholamine assay.
ADH assay. All blood samples for ADH were drawn into syringes that contained EDTA, then transferred to clean tubes on ice. These samples were centrifuged at 4°C for 10 min at 2,000 rpm (model PR-J, International Equipment Co.); the plasma was removed, measured for volume, and frozen at -200C. Within 5 d the sample was thawed, 1.0 ml was removed and acidified with 0.2 ml 1 N hydrochloric acid, and then 1.0 ml of Bentonite (3.0 mg/cm3, Fisher Scientific Co., Pittsburgh, Pa.) was added. The tubes were then vortexed and centrifuged. The supernate was discarded and the Bentonite resuspended in a solution of 1.0 ml of 80% acetone in 1 N hydrochloric acid. After centrifugation and removal of the supernate, the precipitate was washed with 1.0 ml of ether. The ether layer was then aspirated and discarded. The aqueous layer was blown to dryness under room air. The dry residue was stored at -20°C until it was assayed for ADH. The assay for ADH was performed by radioimmunoassay as previously described in our laboratory (26) .
The vasopressin antiserum used in this radioimmunoassay cross-reacts by <0.1% with vasotocin and oxytocin and 10% with lysine vasopressin. The recovery of immunoassayable arginine vasopressin is 79% over a range of 0.8-5.0 .IdU/ml.
The intra-assay coefficient of variation ranges from 6 to 14% and the interassay coefficient of variation ranges from 14 to 29%. The threshold sensitivity of the assay is 0.25,IU/ml, which is significantly different from the blank plasma.
Assay ofpituitary ADH content. On day 12 after the intraventricular injections, the six animals in each group (control and 6-OHDA) that were included in the balance studies were guillotined and their pituitaries were rapidly removed for determination of ADH content. Simultaneous truncal blood was obtained for determination of serum osmolality by freezing-point depression. The pituitary glands were removed rapidly, placed individually in 0.5 ml of0.1 M HCl, and frozen immediately at -800C. At the time of assay, the samples were thawed quickly in a 300C water bath and homogenized. Two 0. 1-ml aliquots of the tissue suspension then were removed. The first aliquot was centrifuged at 3,000 rpm for 30 min. 10 gl of the supemate was removed and dried under air, then reconstituted to 1 ml and diluted 1:100 with assay buffer (26) . The assay for ADH was then performed with 50-and 100-,il aliquots of this sample.
A second 0.1-ml aliquot of tissue suspension underwent the following extraction procedure before ADH assay. As above, 0.5 ml of 0.1 M HCl was added to the 0.1-ml tissue suspension aliquot. 2 ml of acetone was then added to the suspension, which was then vortexed and centrifuged at 3,000 rpm for 10 min. The supernate was then decanted and washed twice with 2 ml ofether. The ether layer was aspirated after each wash. The aqueous layer was then reconstituted to 1 ml and diluted 1:1,000 with assay buffer. The ADH assay was then performed with 50-and 100-,ul aliquots of this sample. Recovery of a known amount of 1251-labeled arginine vasopressin added before the extraction procedure to the tissue suspension averaged 75.2% for four determinations.
Samples of both Sprague-Dawley cortical brain tissue as well as pituitary tissue from a homozygous diabetes insipidus rat (Brattleboro strain) were measured concomitantly with the experimental samples by both methods. ADH content in these
Assay of tissue catecholamines. Brain and heart tissue from 6-OHDA-injected and control-injected animals were prepared for catecholamine (norepinephrine) assay. The heart was used as a reference to establish whether or not the catecholamine-depleting action of 6-OHDA had crossed the blood-brain barrier. The catecholamine assay used was the radioenzymatic technique of Henry et al. (27) , as modified by Arnold et al. (28) .
Immediately after sacrifice the whole brain wvas removed and weighed. The tissues were homogenized at 4°C (Polytron, Brinkman Instruments, Inc., Westbury, N. Y.) in saline, and then the samples were made up to 0.1 N perchloric acid. The samples were frozen until the assay was performed. The assay was performed with only slight variation in the originally reported reaction mixture (28 It can be seen that the brains ofanimals that received intraventricular 6-OHDA had a 67% depletion of assayed norepinephrine. This agrees with literature values for animals treated in a similar fashion (20, 22) . Furthermore, other authors have shown that such animals also have a 60-75% depletion in assayed brain dopamine (20, 22) .
The values for heart norepinephrine revealed that there was no significant depletion in the 6-OHDA rats as compared with control-injected rats. This finding indicates that the catecholamine-depleting effect of intraventricular 6-OHDA is restricted to the brain. Similarly treated animals also have been shown by other investigators (22) to have no depletion in assayed heart dopamine.
Hypertonic saline stimulation. The responses of Posm and Uosm to hypertonic saline administration are shown in Fig. 1 . During base-line water diuresis there were no significant differences in the Posm and Uosm between the control-injected and 6-OHDA-injected rats. There was an equivalent rise in Posm of -15 mosmol/kg H20 in both animal groups when measured 10 min after the hypertonic saline infusion. However, the peak Uosm after hypertonic saline in the controlinjected and 6-OHDA-injected rats was significantly different (586 vs. 335 mosmol/kg H20, P < 0.001). was a modest but significant fall in inulin clearance in the control-injected group.
The results of the plasma ADH levels are shown in Fig. 3 . These results were obtained from four separate groups of animals. Base-line measurements before intravenous hydration of Posm, Hct, and blood pressure were not different in 6-OHDA-injected or controlinjected rats used in this protocol as compared with those rats used to assess maximal Uosm after hypertonic saline administration. Thus, base-line hydration appeared comparable in all rats used in these protocols. In both the control and 6-OHDA-treated rats, plasma ADH levels were drawn during water diuresis or after the hypertonic saline infusion. The water-diuresing rats of both groups had base-line ADH levels as measured by radioimmunoassay that were not significantly different from zero. The control-injected animals had a mean ADH response 20 min after hypertonic saline administration of 7.6 ,uIU/ml, whereas the 6-OHDA-injected rats had an ADH response after hypertonic saline of 2.9 ,uIU/ml, a value significantly less (P < 0.005) than in the control animals. At the time plasma ADH levels were obtained, Posm were comparable in the control vs. 6-OHDA-injected animals (290 vs. 289 mosmol/ kg H20, respectively).
Hyperoncotic dextran administration. The change in BV induced by hyperoncotic dextran administered intraperitoneally is shown in Fig. 4 . Both injection groups showed a decrease of -10% in BV after dextran at the time at which peak Uosm was obtained.
The response in peak Uosm to the dextran administration is shown in Fig. 5 for both groups. Equivalently low Uosm were present in both groups during water diuresis. However, control-injected rats concentrated their urine to a mean of 753 mosmol/kg H20 after dextran, whereas 6-OHDA-injected rats concentrated their urine to only 358 mosmol/kg H20 (P < 0.001). There was no significant difference in mean Posm between the control and 6-OHDA animals in response to intraperitoneal dextran (290 vs. 288 mosmol/kg H20 control and 291 vs. 289 mosmol/kg H20 6-OHDA, respectively). Mean arterial pressure and inulin clearance for each group are shown in Fig. 6 . Both injection groups had equivalent mean arterial pressure and inulin clearance during water diuresis and after dextran administration.
The plasma ADH results for the hyperoncotic dextran In-5) (n 9) FIGURE 7 Plasma ADH levels for water-diuresing (columns labeled "control diuresis" and "6-OHDA diuresis") and dextran-stimulated (columns labeled "control dextran" and "6-OHDA dextran") animals. (20, 22) . In our investigation a 67% decrease in brain catecholamines occurred without concomitant extracerebral catecholamine depletion, as documented by the demonstration of no alteration in heart catecholamines. Of equal importance is the observation that there was no difference in behavior between control-injected and 6-OHDA-injected rats treated comparably to those used in the acute experimental protocols. Changes in weight, mean food intake, and serial blood pressures were identical in the two groups of animals. Although water intake aind urine volumes were slightly decreased in 6-OHDA-injected vs. control-injected rats, serum osmolality and pituitary ADH content were not different in the two groups of animals. Taken together, these results indicate that the observed differences in response to osmotic and nonosmotic stimuli were not a result of nonspecific effects of the 6-OHDA, such as chronic dehydration, resulting in depletion of pituitary ADH content.
Arterial blood pressure and renal hemodynamics were monitored before and after producing the osmotic and nonosmotic stimuli in both control-injected and 6-OHDA-injected rats. The mean arterial blood pressure, renal hemodynamics, and urinary diluting capacity were no different in the control and treated animals either before or after the stimulus for ADH release. These comparable findings in the control and 6-OHDA animals allowed for changes in Uosm to be monitored as an index of the end organ response to ADH. A sensitive and specific radioimmunoassay for ADH was used to monitor plasma changes in this hormone in response to osmotic and nonosmotic stimuli (26) .
It was also important to test both the osmotic and nonosmotic response to ADH release because there is now evidence that these stimuli are mediated through different pathways. As discussed earlier, there is experimental evidence that both high (arterial) (26, 32, 33) and low (atrial) (34, 35) pressure baroreceptors are involved in mediating a variety of nonosmotic stimuli. These pathways, however, are clearly not involved in the osmotic stimulation of ADH release because \Terney (2) originally demonstrated that baroreceptor denervation does not alter the ADH response to the injection of intracarotid hypertonic solutions. Moreover, there is now evidence in man that the osmotic release of ADH can be virtually abolished, while at the same time the nonosmotic release of ADH is perfectly normal (36) . It is thus possible that catecholamines might be important as neurotransmitters in either the osmoreceptor or nonosmotic baroreceptor-mediated changes in ADH release, or both. Lastly, to examine the best sensitivity for osmotic and nonosmotic ADH release, the studies were performed in conscious rats.
The results of our study demonstrated that the same osmotic stimulus with hypertonic saline was associated with an attenuated release of ADH in the 6-OHDA animals as comnpared with the vehicle-treated control animals. The diminished release of ADH was associated with an appropriately lower Uosm in the 6-OHDA animals which could not be accounted for by differences in systemic or renal hemodynamics. Similar results were obtained when hyperoncotic dextran was used to cause hypovolemia and stimulate the nonosmotic release of ADH. This maneuver produced at least a 10% decrease in BV in both groups of animals; our results, therefore, confirm earlier studies in the rat which indicate that such a fall in BV consistently stimulates ADH release (37) . As in the hypertonic saline studies, the attenuated release of ADH in response to the nonosmotic hypovolemic stimulus was associated with an appropriately lower Uosin in the 6-OHDA-treated animals as compared with control animals. These different effects on ADH release and Uosm in response to the nonosmotic stimulus also couild not be attributed to differences in measuired systemic or renal hemodynamics.
It was not possible in our study to compare quantitatively the ADH response to an osmotic vs. a nonosmotic stimulus because different temporal relationships for measuring ADH were necessary in the two groups. The ADH values also were drawn at the time of peak Uosm and, thus, do not necessarily reflect maximal plasma levels. Moreover, the variability in the maximal response in the nonosmotic hypovolemic studies necessitated a method of measuring the mean plasma ADH level over a period of 30 mini. On the other hand, the timing of the osmotic stimulus was consistently predictable, allowing ADH values in the hypertonic saline studies to be meastured at a constant interval after the peak osmotic stimulus. In each case, however, it must be emphasized that the timing of collection for plasma ADLI measurements was the same in the control and 6-OHDA groups and therefore couild not explain the differences in responses. It should also be mentioned that further studies will be necessary to incriminate the specific catecholamine for the osmotic and nonosmotic stimuli because 6-OHDA is known to deplete both brain norepinephrine and dopamine. Moreover, as with all drug inhibitors, it is possible that the effect of 6-OHDA might alter ADH release in response to osmotic and nonosmotic stimuli by an as yet undefined mechanism. In this regard, Hoffman et al. (38) have suggested that 6-OHDA attenuates the response of ADH to intraventricular angiotensin II by directly altering central neuiron integrity.
In conclusion, our results demonstrate that brain catecholamine depletion with 6-OHDA attenuates both the acute osmotic (hypertonic saline) and nonosmotic (hypovolemia secondary to intraperitoneal dextran) stimuilation of ADH release. This attenuation could not be attributable to either alterations in arterial blood pressure or glomerular filtration rate, or the base-line pituitary ADH depletion. The failure to abolish totally the ADH release to these stimuli may be becauise of the fact that the brain catecholamines were only 67% depleted. Alternatively, other, perhaps secondary, pathways for ADH release may exist which are independent of hypothalaniic catecholamines. In either case, a critical role of brain catecholamines in ADH release to osmotic and nionosmotic stimuli is implicated by our results.
